Cholesterol Biosynthesis from Lanosterol

A CONCERTED ROLE FOR Sp1 AND NF-Y-BINDING SITES FOR STEROL-MEDIATED REGULATION OF RAT 7-DEHYDROCHOLESTEROL REDUCTASE GENE EXPRESSION*

Jai-Hyun Kim, Joon No Lee, and Young-Ki PaikDagger

From the Department of Biochemistry, Bioproducts Research Center and Yonsei Proteome Research Center, Yonsei University, 134 Shinchon-dong, Sudaemoon-ku, Seoul 120-749, Korea

Received for publication, February 22, 2000, and in revised form, March 12, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The 7-dehydrocholesterol reductase (Dhcr7) is the terminal enzyme in the pathway of cholesterol biosynthesis. We have previously reported that sterol depletion in vivo caused a significant induction of both liver mRNA and enzyme activity of Dhcr7 (Bae, S.-H., Lee, J. N., Fitzky, B. U., Seong, J., and Paik, Y.-K. (1999) J. Biol. Chem. 274, 14624-14631). In this paper, we also observed liver cell-specific sterol-mediated Dhcr7 gene induction in vitro by sterol depletion in rat hepatoma cells, suggesting the presence of sterol-mediated regulatory elements in the Dhcr7 gene. To understand the mechanisms responsible for regulating Dhcr7 expression, we have isolated the 5'-flanking region of the gene encoding rat Dhcr7 and have characterized the potential regulatory elements of the gene that are responsible for sterol-mediated regulation. The Dhcr7 promoter contains binding sites for Sp1 (at -177, -172, -125, and -20), NF-Y (at -88 and -51), and SREBP-1 or ADD1 (at -33). Deletion analysis of the Dhcr7 gene promoter (-1053/+31), employing a nested series of Dhcr7-luciferase constructs, demonstrated that the -179 upstream region of the gene is necessary and sufficient for optimal efficient sterol-regulated transcription. DNase I footprinting and electrophoretic mobility shift assay showed that the SRE1/E box (-33/-22) involved in sterol response of many sterol-related enzyme genes was protected specifically by the overexpressed recombinant ADD1. Mutational analysis for the functional relationship between the identified cis-elements in this region indicate that one of the binding sites for Sp1 (GC box at -125) and NF-Y (CCAAT box at -88) plays a cooperative role in the sterol-mediated activation, in which the latter site also acts as a co-regulator for SREBP-activated Dhcr7 promoter activity. We believe that Dhcr7 is the first enzyme characterized with a sterol-regulatory function in the post-lanosterol pathway. This may be important for understanding the coordinated control of cholesterol biosynthesis as well as the molecular mechanism of Smith-Lemli-Opitz syndrome-related protein in mammals.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The 7-dehydrocholesterol reductase (Dhcr7,1 EC 1.3.1.21) catalyzes the reduction of the Delta 7-double bond of sterol intermediates, which is the terminal reaction, in the pathway of cholesterol biosynthesis from lanosterol (1-3). Studies of this enzyme have recently drawn our attention due to its implication in both cholesterol metabolism and mammalian developmental biology (4-6). In particular, mutations of Dhcr7 has been involved in genetic disease such as Smith-Lemi-Opitz syndrome (SLOS) (7-9), which is an autosomal recessive disorder with various developmental abnormalities. SLOS is characterized by elevated 7-dehydrocholesterol in serum (10-18). This connection between cholesterol and the developmental program in mammals was established based on the critical role of cholesterol in autoprocessing of sonic hedgehog (shh) protein (5, 6, 19), a morphogen, which binds to, patched protein in developing the central nervous system and limbs. For example, the mouse mutated in shh showed SLOS-like phenotype (20, 21).

Recently, cDNAs encoding Dhcr7 from mouse (22), rat (4), human (7), and Arabidopsis thaliana (23) have been isolated. Dhcr7 mRNA was expressed mainly in liver and its regulation appeared to be controlled by tissue sterol contents as well as some cholesterogenic inhibitors (2, 4). However, molecular cloning and the nature of sterol-mediated transcriptional control of the Dhcr7 gene in any species have not been reported previously. Furthermore, the relative importance of multiple motifs at the 5'-flanking region in transcriptional regulation of the Dhcr7 gene is also not known. In order to characterize the 5'-flanking region and the response of multiple regulatory elements to sterols, we isolated the 5'-flanking region of the rat Dhcr7 gene and the complete genomic sequence (GenBankTM accession number AF279892).2 In this paper, we describe the promoter activity and the sterol-mediated regulation of this gene by various mutation analyses, with emphasis on the proximal promoter (-179 to +1), which controls transcriptional induction of the gene in response to starvation of cellular sterols.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- A rat Promoter FinderTM DNA Walking Kit was purchased from CLONTECH (Palo Alto, CA). The following materials were purchased from manufacturers, as indicated. Hyper x-ray film, [alpha -32P]dCTP (3000 Ci/mmol), [gamma -32P]ATP (3000 Ci/mmol), poly(dI-dC) ·poly(dI-dC), Amersham Pharmacia Biotech; DNA sequencing reagents, PerkinElmer Life Sciences; restriction endonucleases, T4-DNA ligase, T4-polynucleotide kinase, and Klenow fragment of DNA polymerase I, New England Biolabs; RNasin ribonuclease inhibitor and avian myeloblastosis virus-reverse transcriptase, Promega; lipoprotein-deficient serum (LPDS), Sigma; Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), gentamycin, and L-glutamine, Life Technologies; sterols including cholesterol and various oxysterols including 25-, 20-, 19-, 4-, 7alpha -, 7beta -hydroxycholesterols, 6-keto, and 7-keto-sterols, Steraloid. The sources of the following drugs or agents are also indicated. AY-9944, Dr. D. Dvornik at Wyth-Ayerst, Princeton; and LovastatinTM, Dr. Y-K. Sim at Choongwae Pharmaceutical Co., Korea.

RNA Preparation and Northern Blot Analysis-- RNA was isolated by phenol-chloroform extraction using TRI reagent Kit (Molecular Research Center Inc.). Total RNA (20 µg) was electrophoresed in a 1% formaldehyde-agarose gel and vacuum-transferred to Hybond N+ membrane (Amersham Pharmacia Biotech) with 20 × SSC (150 mM NaCl, 15 mM sodium citrate, pH 7.0). After prehybridization of the membranes at 42 °C for 5 h in 5 × SSC, 10 × Denhardt's solution, 100 µg/ml denatured herring sperm DNA, the membranes were hybridized to 32P-labeled rat Dhcr7 cDNA probe for 18 h. Then the membranes were washed with 0.1% SSC, 0.1% SDS at 65 °C. Hybridization signals were visualized by autoradiography using Hyper x-ray film with an intensifying screen at -70 °C. The signals that appeared in the membranes were quantitatively analyzed with a BAS 2500 system (Fuji Photo Film Co.) and normalized to the quantity of beta -actin mRNA expression.

Cloning of the 5'-Flanking Region of the Rat Dhcr7 Gene-- At the initial stage of this work, rat Dhcr7 promoter was amplified from DNA provided in the rat Promoter FinderTM DNA walking kit (CLONTECH) according to the manufacturer's instructions. The primer r7R-9 (+49 ~ +28) 5'-GCGTGCGGGATCCGGGCGGTTG-3', corresponding to the cDNA for rat Dhcr7, and anchor primer AP1 of the promoter finder kit were used in the primary PCR. The primary PCR products were diluted and used for the secondary PCR with nested primer r7R-48 (+31 ~ +7) 5'-GTTGATTCCAAGCTCCAGCAGCGCC-3' in the 5' region of Dhcr7 and anchor primer AP2. Secondary PCR products were cloned into pT7Blue(R)-T vector and sequenced with an ABI automated DNA sequencing system. The cloned Dhcr7 promoter region was also confirmed by data obtained from genomic clone sequencing.

Construction of Dhcr7-Luciferase Recombinant Plasmids-- To analyze Dhcr7 promoter, the 5'-flanking region of the gene was ligated into the luciferase reporter vector as follows. The parent plasmid, p7R1084, was constructed by Klenow enzyme treatment of a DNA fragment (NdeI/EcoRI) spanning -1053 to +31 nucleotides, followed by insertion into the SmaI site of the luciferase vector pGL3-Basic (Promega). Plasmid p7R1084 (-1053/+31) was digested with NheI and PvuII to remove the 5'-fragment (NheI/PvuII) of the Dhcr7 insert, and religated after treatment with T4 DNA polymerase to produce p7R537 (-506/+31). In the same manner, p7R1084 was digested with PstI, BstXI, and ApaI, and religated to produce p7R318 (-287/+31), p7R210 (-179/+31), and p7R148 (-117/+31), respectively. Plasmid p7R164 (-133/+31) and p7R72 (-41/+31) were generated by cloning PCR products obtained by using appropriate synthetic oligonucleotides into a SmaI-digested pGL3-Basic vector. The truncated chimeric plasmid p7R287-117 was prepared by inserting a 171-bp PstI/ApaI fragement of p7R1084 into a SmaI-digested pGL3-Basic vector. All luciferase reporter genes except p7R287-117 had the same 3' end in a SmaI site of pGL3-Basic and varying 5' ends. All plasmids were verified by DNA sequencing.

Mutation Analysis of the Promoter Region-- The various mutant constructs were generated by PCR using the wild type Dhcr7 promoter DNA as a template with Pfu polymerase and mutagenic oligonucleotides designed to introduce each specific multibase point mutation. The mutated Dhcr7 promoter constructs were designated as M1 to M14. The sequences of the oligonucleotides used for the mutation of the different parts of the Dhcr7 promoter are shown below, with the mutated sequences in bold: SRE/m (-46/-18); 5'-GTAGTCTGTGACCAGTAATCACCTGGGGG-3', E box/m (-46/-18); 5'-GTAGTCTGTGACCTCACGTCACTACGGGG-3', SRE·E box/m (-46/-18); 5'-GTAGTCTGTGACCAGTAATCACTACGGGG-3', ADD/m (-46/-18); 5'-GTAGTCTGTTCCCAGTAATTCGTACGGGG-3', NFY/m (-64/-33); 5'-GAAATCCACTTCGGAGATCTAGTCTGTGACCT-3', GC1·2/m (-191/-156); 5'-GTCCCCAGGGGCGTGGGATGGTTGGGGCTGGCCCTG-3', CCAAT/m (-100/-69); 5'-GCTCACTGCCTTCAGATCTCACAGGGCGCGG-3', GC3/m (-135/-109); 5'-GCCGCCGACTGTATTGCCCGGTGGGCT-3', GC4/m (-29/-3); 5'-GTCACCTGGGTTGAGTGCTTCAGGCAG-3', SRE/m1 (-46/-18); 5'-GTAGTCTGTGACCTCACGTTCGCTGGGGG-3', SRE/m2 (-46/-18); 5'-GTAGTCTGTGACCAGTAATTCGCTGGGGG-3'. The PCR reaction products were digested with restriction enzymes and inserted into the luciferase vector pGL3-Basic. The DNA sequence of each mutant clone was confirmed by sequencing.

Cell Culture and Transfection of Cells-- HepG2, CHO-K1, and H4IIE cells were grown in RPMI medium 1640 (Life Technologies, Inc.) supplemented with 5% (v/v) FBS, 1 mM glutamine, and 10 µg/ml gentamycin in a 5% CO2 incubator at 37 °C. Cells plated onto 6-well plates were grown to 50-70% confluence before transfection. Two µg of test constructs were co-transfected into HepG2 cells with 0.2 µg of Renilla luciferase control vector, pRL-SV40 (Promega). Each plasmid containing Dhcr7 promoter-luciferase fusion gene and 2.0 µl of Lipofectin reagent (Life Technologies) was diluted into 80 µl of Opti-MEM I (Life Technologies). Plasmid DNA and Lipofectin reagent were then combined and added to each plate according to the Lipofectin manufacturer recommendations. The cells were transfected on serum-free media for 18 h and then were switched to a medium with 5% LPDS plus 10 µM Lovastatin (designated as sterol starvation condition) or 1.5 µg/ml 25-hydroxycholesterol (designated as sterol rich condition). After incubation for 48 h, with the appropriate medium, cells were harvested, and extracts were assayed for luciferase activity (see below for details).

Preparation of Cell Extracts and Luciferase Enzyme Assays-- Following transfection and drug treatment, the cells were washed with phosphate-buffered saline and lysed in 0.5 ml of 1 × passive lysis buffer (Promega). Cell extracts were assayed for Firefly and Renilla luciferase activities using the Dual-luciferase Reporter Assay SystemTM according to the manufacturer's recommendations (Promega). Amounts of lysates employed for the Firefly luciferase activity assays of test constructs were normalized to the Renilla luciferase activities.

DNase I Footprinting Assays-- 32P-Labeled DNA probes (-258/+41) were prepared from Dhcr7 gene and incubated with 0.2 or 2 µg of purified ADD1 protein in Buffer A (10 mM Tris (pH 7.6), 100 mM KCl, 10 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, and 4 µg of poly(dI-dC)·poly(dI-dC)) at room temperature for 30 min in a total volume of 20 µl. At the end of the reaction, 80 µl of a solution containing 3 mM CaCl2 and 6 mM MgCl2 was added the mixture. After digestion with DNase I, the DNA samples were extracted by a phenol/chloroform solution and electrophoresed on a 6% sequencing gel with a same end-labeled sequencing ladder.

Electrophoretic Mobility Shift Assays (EMSA)-- Recombinant ADD1 (amino acid residues 284 to 403 including the bHLH-LZ domain) was overexpressed in Escherichia coli and purified from the culture extracts as described previously (24). Rat hepatoma H4IIE cell nuclear extracts were prepared according to the method of Dignam et al. (25). Nuclear extracts were quantified by the Bradford assay (Bio-Rad) and stored at -70 °C. For EMSA, annealed oligonucleotide probes were 5'-end labeled using [gamma -32P]ATP by T4-ploynucleotide kinase. Binding reactions were carried out in Buffer A in the presence of 1 mg/ml bovine serum albumin. Approximately 0.1 pmol of the labeled probe was mixed with 2-6 µg of nuclear extract or 10-100 ng of recombinant ADD1 in 20 µl, then incubated for 30 min at room temperature. EMSA was performed on a 5% polyacrylamide gel with 0.5 × TBE buffer (40 mM Tris borate, 1 mM EDTA) and processed for autoradiography. For binding competition assays, 100-fold molar excess of unlabeled oligonucleotides were added before the addition of labeled probe. The DNA sequence of oligonucleotides used were as follows: ADD (ADD1-binding site of Dhcr7 promoter), 5'-GTAGTCTGTGACCTCACGTCACCTGGGGG-3'; GC3 (Sp1-binding site of Dhcr7 promoter), 5'-CGCCGACTGGCGGGCCCGGTGG-3'; CCAAT1 (NF-Y-binding site of Dhcr7 promoter), 5'-CTGCCTTCACCAATCACAGGGC-3'; GC-box (Sp1-binding site), 5'-ATTCGATCGGGGCGGGGCGAGC-3'; CCAAT box (NF-Y binding site), 5'-GTGATCAGCCAATCAGAGCGAG-3'; ABS (ADD1-binding site: E box), 5'-GATCCTGATCACGTGATCGAGGAG-3'; and SRE-1, 5'-GATCCTGATCACCCCACTGAGGAG-3'.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Induction of Dhcr7 Gene by Sterol Starvation-- We have previously reported (4) that when rats were maintained on a sterol starvation condition by feeding CL-diet (5% (w/w) cholestyramine plus 0.1% (w/w) Lovastatin in chow) for 14 days, both hepatic mRNA expression and the specific enzyme activity of Dhcr7 were increased in vivo about 3- and 5-fold, respectively. To examine if this type of sterol-mediated Dhcr7 induction can also be seen in cultured cells in vitro, Northern blot analysis was performed using Dhcr7 mRNA obtained from H4IIE cells and CHO-K1 cells that had been maintained in either FBS or LPDS medium. As shown in Fig. 1A, mRNA from the Dhcr7 gene was specifically induced more than 3-fold in H4IIE cells (hepatic cells). However, this induction by sterol depletion was seen only slightly in CHO-K1 cells (non-hepatic cells). Dhcr7 mRNA was highly inducible in a dose-dependent manner when cells were grown under sterol starvation conditions, where cells were treated with the two cholesterogenic enzyme inhibitors, AY-9944 (Dhcr7 inhibitor) and Lovastatin (HMG-CoA reductase inhibitor) (Fig. 1, B and C). In contrast to this observation, the Dhcr7 gene was suppressed by treatment of cells with 25-hydroxycholesterol (Fig. 1D). These results predicted sterol-mediated regulatory sequences in the Dhcr7 gene. To test this possibility, we isolated and analyzed the 5'-flanking region of this gene in detail.


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of LPDS medium, sterol and cholesterol-lowering drugs on expression of Dhcr7 mRNA. A, after H4IIE and CHO-K1 were incubated for 24 h in either FBS or LPDS medium at 70% confluence, total RNA was isolated from the cells. Twenty µg of the total RNAs were electrophoresed on a 1% agarose gel and transferred to a Hybond N+ membrane. The filter was hybridized with 32P-labeled rat Dhcr7 cDNA probe and exposed to film. The same filter was subsequently hybridized with beta -actin probe. B and C, H4IIE cells were cultured in normal medium containing 0, 0.01, 0.1, and 1 µM AY9944 (lanes 1-4 (B), or LPDS medium containing 0, 0.01, 0.1, 1, 10 µM Lovastatin (lanes 1-5 (C)). After 24 h incubation, total RNA was prepared from the cells and 20 µg of RNA subjected to Northern blot analysis. D, H4IIE cells were cultured in LPDS medium containing 0, 0.01, 0.05, 0.1, and 0.5 µg/ml 25-hydoxycholesterol (lanes 1-5 (D)). After 24 h incubation, total RNA was prepared from the cells and 20 µg of RNA subjected to Northern blot analysis. 25-OH, 25-hydroxycholesterol.

Mapping of Multiple Sterol-responsive Motifs-- A 1.1-kilobase upstream fragment of the putative transcription initiation site from the rat genomic clone was isolated, sequenced, and analyzed to identify several cis-acting regulatory elements. The transcription initiation site was previously determined.2 The nucleotide sequence (1,053 bp), including exon 1, its 5'-flanking region, and part of intron 1, is shown (Fig. 2). The proximal region (-179 to +1) is 67% G + C and contains several well known transcription factor binding sites (Fig. 2). These are four GC boxes binding to Sp1 (-177/-172 (GC1), -172/-167 (GC2), -125/-121 (GC3), and -20/-15(GC4)), two CCAAT boxes binding to NF-Y (-88/-81 (CCAAT1) and -51/-45 (inverted, CCAAT2)) and an SRE1/E box binding to SREBP-1 or ADD1 (-33/-22). These regulatory sites are regarded as typical motifs seen in several genes involved in cholesterol homeostasis (26-34). There was no TATA box within the promoter region of the Dhcr7, implying the presence of multiple transcription start sites as previously demonstrated.2 The transcription start site by the longest 5'-rapid amplification of cDNA ends product is located at an adenine (A) residue, which is 307 bp away from the ATG codon in Dhcr7 cDNA2 (Fig. 2). Therefore, Dhcr7 gene transcription appears to be driven by a TATA-less GC-rich promoter. This 5'-flanking region of the Dhcr7 promoter (-1053 to +1) also contains other well characterized regulatory elements that may control expression of this gene. These include two AP-1 (-454/-449 and -130/-125), four AP-4 (-510/-505, -290/-284, -167/-162, and -103/-98), NF-1 (-422/-417), NFAT (-555/-550), and SRY (-521/-516) binding sites. There are many IK2 and MZF-1-binding sites in the Dhcr7 promoter and part of intron 1. With regard to sterol-mediated regulation, we have focused on the proximal region (-179/+1) for further analysis on Dhcr7 gene transcription.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 2.   Nucleotide sequence of the 5'-flanking region of rat Dhcr7 gene. The sequence shown contains 1053 nucleotides 5' to the transcription start site of the longest mRNA transcript. The adenine at the transcription start site is designated +1. Putative transcriptional regulatory elements are underlined and identified below the sequences in bold letters.

Deletion Analysis of Dhcr7-Luciferase Recombinant DNA for Sterol-response Regulation-- To identify the transcriptional regulatory regions in rat Dhcr7 gene and to determine whether this region is regulated by exogenous sterols, a nested series of fragments containing various lengths of the 5'-flanking region, together with a part of the first exon (+31 out of 52 bp) were generated by either PCR or restriction endonuclease digestion. The parental plasmid used for this study was designated as p7R1084, spanning nucleotides -1053 to +31. Each deletion construct was prepared by inserting DNA fragments of various lengths into the luciferase gene and then analyzed for promoter activity using a transient assay system, as described under "Experimental Procedures." These deletion constructs were transfected into HepG2 cells and their luciferase activities measured following treatment with sterols (Fig. 3). To normalize activity in different transfected cells, we co-transfected the cells with pRL-SV40, a non sterol-regulated Renilla luciferase expression vector. Results were expressed as "-fold" activation by taking the ratio of the luciferase activities after sterol starvation (-sterol) or sterol supplemented (+sterol) conditions. For the analysis of the regulation of the Dhcr7 promoter, HepG2 cells were chosen due to their relatively high transfection efficiency (>30-fold) as compared with that of H4IIE cells (data not shown). The promoter activity of the longest fragment, beginning at -1053 (p7R1084), was set at 100% for the results obtained from HepG2 cells in 5% LPDS (plus 10 µM Lovastatin; sterol starvation condition). The basal promoter activity was set at the luciferase activity of p7R72 (-41/+31). As shown in Fig. 3, the promoter activity of the parent construct (p7R1084) was decreased more than 11-fold when sterol (1.5 µg/ml 25-hydroxycholesterol) was added into the LPDS media, confirming the presence of sterol-mediated regulatory elements such as the SRE1/E box located at -33/-22 in the 5'-flanking region (Fig. 2). Deletion of regions spanning nucleotides -1053 and -133 (p7R537, p7R318, p7R210, and p7R164) caused no significant change in either promoter activity or sterol-mediated activation of Dhcr7 promoter activity. However, deletion of nucleotides between -133 and -117 caused almost a 3.5-fold reduction in both the promoter activity relative to the -133 region and the sterol-mediated activation. That is, there was a change in the magnitude of sterol-mediated activation between these two constructs (-133/+31 (13.6-fold) versus -117/+31 (4.0-fold)). This result suggests the presence of positive cis-acting sequences in this region (-133 and -117), which seems sensitive to the absence of sterol. This is further confirmed by the fact that the deletion constructs, p7R148 (-117/+31) and p7R72 (-41/+31), almost abolished a sterol-mediated activation (~4.0 to ~2.9-fold). Therefore, it appears that the two tandem repeat GC boxes at -177 (GC1) and -172 (GC2) are less important than other proximal GC boxes (e.g. GC3) for Dhcr7 promoter activity in response to sterols. Addition of the fragment containing sterol-regulated regions which enhanced activity (-287/-117) of the reporter gene itself (pGL3-Basic vector; e.g. p7R287-117), exhibited much lower luciferase activity in the absence of sterol than that of basal promoter construct, suggesting the absence of promoter activity in this sequence. A similar pattern of expression was also observed for these constructs when they were transfected into either CHO-K1 cells or H4IIE cells (Fig. 4). Therefore, we have focused on nucleotides spanning -287 to +31 (p7R318 showed the highest activity on sterol depletion conditions) in the 5'-flanking region of the rat Dhcr7 gene for further analysis of sterol response.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   Relative promoter activity and response to sterols of Dhcr7 promoter luciferase-chimeric genes. Luciferase activities were measured in HepG2 cells that had been transfected with both a Dhcr7 promoter-luciferase construct and a pRL-SV40 plasmid (Promega) as an internal control in the presence or absence of sterols. Relative luciferase activities were determined as a ratio of luciferase activity of each sample to the activity of Renilla luciferase and were normalized to 100 for p7R1084 in the absence of sterols. For the starvation of sterols, cells were incubated in 5% LPDS containing media in the presence of 10 µM Lovastatin. In the presence of sterols, cells were incubated in the same LPDS media in the presence of 1.5 µg/ml 25-hydroxycholesterol. Values shown here are the mean ± S.D. (n = 4).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of promoter activities of fusion genes containing varying lengths of the Dhcr7 promoter in HepG2, H4IIE, and CHO-K1. Cells were co-transfected with one of the chimeric genes p7R1084, p7R537, p7R318, p7R210, p7R164, p7R148, p7R72, or p7R287-117 and with a pRL-SV40 plasmid for an internal control. Cells were maintained in LPDS-containing media in the presence of 10 µM Lovastatin. Relative luciferase activities were determined as a ratio of luciferase activity of each sample to the activity of Renilla luciferase and were normalized to 100 for p7R1084 in all cells. The relative activity of p7R1084 in HepG2 was 1.4 and 3.8 times higher than in H4IIE and CHO-K1 cells. Values shown here are the mean from three independent experiments.

To examine which oxysterol may be most effective in suppression of the Dhcr7 promoter, luciferase activities were measured for p7R318 (-287/+31) in the presence of different oxysterols. As shown in Fig. 5, 25-hydroxycholesterol was found to be the strongest regulator among the seven oxysterols examined. However, the addition of Dhcr7 inhibitor (AY-9944, 2 µM) or HMG-CoA reductase inhibitor (lovastatin, 20 µM) to the LPDS media (sterol depletion conditions) resulted in increases of 150 and 180% in HepG2 cells that had been transfected with p7R318. The concentration of Lovastatin or AY-9944 was empirically determined prior to this experiment. These results are consistent with those of endogenous mRNA expression under similar conditions (Fig. 1, B and C). As expected, addition of 25-hydroxycholesterol to LPDS medium abolished the AY-9944- or Lovastatin-induced activation of Dhcr7 promoter activity (Fig. 5), suggesting a dominant suppressive role for 25-hydroxycholesterol. In FBS medium (a sterol-supplemented condition), Lovastatin (HMG-CoA reductase inhibitor) produced a 3-fold increase of Dhcr7 promoter activity; AY-9944 (Dhcr7 inhibitor) only resulted in 1.3-fold induction, implying a different mode of action for these inhibitors in FBS media.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 5.   Expression of luciferase reporter gene containing rat Dhcr7 promoter in HepG2 cells maintained in different drugs or sterols, in either LPDS or FBS media. HepG2 cells were transfected with p7R318 (-287/+31) and exposed to medium containing 5% (v/v) LPDS or 5% FBS media supplemented with 1.5 µg/ml 25-hydroxycholesterol (25-OH), 20-hydroxycholesterol (20-OH), 19-hydroxycholesterol (19-OH), 4-hydroxycholesterol (4-OH), 7alpha -hydroxycholesterol (7alpha -OH), 7beta -hydroxycholesterol (7beta -OH), 6-ketosterol (6-keto), 7-ketosterol (7-keto); 10 µg/ml cholesterol (Chol), and the cholesterol biosynthesis inhibitor 2 µM AY-9944 (AY) or 20 µM Lovastatin (Lova). After incubation for 40 h with the appropriate media, the cells were harvested assayed for luciferase activity. Data are the average of two separate determinations.

Interaction of Recombinant ADD1 Transcription Factor with Promoter Sequence of Dhcr7-- To characterize transcription factors binding to the Dhcr7 promoter, ADD1, a rat homolog of human SREBP-1, was overexpressed. DNase I footprinting and EMSA were performed using the DNA fragment covering -258/+41 and a synthetic 29-mer oligonucleotide binding to ADD1. As shown in Fig. 6A, a recombinant ADD1 binds specifically to the proximal promoter specifically in a dose-response fashion, and its binding to the probe was abolished by the addition of 100-fold molar excess of a double-stranded 29-mer oligonucleotide competitor. As shown in Fig. 6B, the sequence elements such as SRE1/E box involved in sterol response of Dhcr7 was protected by overexpressed recombinant ADD1. A footprint covering nucleotides -40 to -22 was clearly visible; this protected region includes the consensus SRE1/E box (-33/-22). The binding of overexpressed ADD1 to the Dhcr7 promoter was also observed by EMSA (Fig. 6C). The annealed double-stranded oligonucleotides probe ADD (-46 to -18), containing SRE1/E box, binds efficiently to ADD1 in EMSA. Its specific binding intensity was reduced in the presence of a 100-fold molar excess of specific competitors such as ABS (contained ADD1-binding site: E box) and SRE-1 consensus sequence (Fig. 6C). However, binding competition was not observed for any of these mutant oligonucleotide competitors (lanes 4-5 in Fig. 6C). These results suggest that the required sequences for binding to the overexpressed ADD1 are located within the nucleotides between -40 and -22, which are overlapped with E box. To examine any binding specificity for Sp1 and NF-Y to the proximal region of Dhcr7 promoter, EMSA was performed using the appropriate probes covering this region in the presence or absence of competitor. Specifically, GC3 at -125 binds to Sp1 and CCAAT1 at -88 binds to NF-Y (Fig. 7, A and B). These results provide direct evidence that sequences proximal to nucleotide -133 serve as binding sites for both Sp1 and NF-Y.


View larger version (78K):
[in this window]
[in a new window]
 
Fig. 6.   SREBP-1/ADD1 binds to sequences in the proximal rat Dhcr7 promoter. A, a probe corresponding to nucleotides -137 to +41 and containing the SRE-1 was generated by PCR from the Dhcr7 promoter. This probe was end-labeled with [alpha -32P]dCTP and incubated with ADD1 (lanes 2 and 3) and competitor double strand-ADD (lane 4). B, the end labeled probe (-258 to +41) was incubated in the absence or presence of recombinant ADD1. DNase I digestion was performed and the resulting products were separated by denaturing polyacrylamide gel electrophoresis with the same end-labeled sequencing ladder. The presence of a DNase I protected region and its corresponding nucleotide sequence are indicated. The proteins added are 0.2 µg (lane 1) and 2 µg (lane 2) of ADD1, and 2 µg of bovine serum albumin (lane 3), respectively. C, EMSA of double strand-ADD by binding to ADD1. The double-stranded oligomer (ds-ADD) containing the SRE-1 sequence was used as the probe. The labeled probe was added into the reaction mixture that contained the recombinant ADD1 and 100-fold molar excess amount of competitor oligonucleotides as described under "Experimental Procedures." Lane 1, unbound ds-ADD probe; lanes 2 and 3 probe incubated with 20 and 100 ng of recombinant ADD1; lanes 4-7, show competition assays. Separation was done by electrophoresis on a 5% native polyacrylamide gel.


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 7.   Sp-1 and NF-Y binding to the GC3 and CCAAT1 sequences in the rat Dhcr7 promoter. EMSA was performed with nuclear extract of H4IIE cells as described under "Experimental Procedures." The 32P-labeled DNA probes (nucleotides -133 to -112: Panel A, -95 to -74: Panel B) were generated by using polynucleotide kinase. Lanes 1 and 5, DNA probe only; lane 2, DNA probe incubated with cell extract; lane 3, same as in lane 2, but the binding reaction contained a 100-fold excess of the consensus GC box (Panel A) or CCAAT box (Panel B) as competitor; lane 4, as in lane 3, except containing mutant competitor at the Sp-1-binding site (Panel A) or NF-Y-binding site (Panel B).

Mutational Analysis of Sterol-mediated Regulatory Sequences within Dhcr7 Promoter-- Fig. 3 demonstrates that the -287 upstream region of the Dhcr7 promoter is both necessary and sufficient for optimal sterol-regulated transcription. To further investigate functional relationships between the identified cis-elements in the Dhcr7 promoter, which are shown to be involved in the sterol-mediated regulation, we introduced a series of multiple point mutations into this region and fused the resulting mutant promoters to a luciferase reporter gene. Each construct was then transiently transfected into HepG2 cells and assayed for sterol-regulated transcription by maintaining the transfected cells either under induced (sterol starvation) or suppressed (supplementation of 25-hydroxycholesterol) conditions. Constructs containing mutations within the region -287 to +1, relative to the transcription start site are shown (Fig. 8), and the ratio of reporter gene activity obtained from either induced or suppressed conditions is reported as -fold activation (-sterol/+sterol). Mutations of the two distal Sp1-binding sites (Delta GC1/GC2; M1), second NF-Y-binding site (Delta CCAAT2; M7), and SREBP/ADD1-binding site (Delta SRE1/E-box; M9-M11) caused no change in sterol-mediated response (Fig. 8). However, mutation of either the third Sp1-binding site (Delta GC3; M2, M3) or the first NF-Y-binding site (Delta CCAAT1; M5, M6) caused a reduction of sterol regulatory response. Mutations of the proximal Sp1-binding site (Delta GC4; M4, M12) and the whole region of SRE1/E box or the SRE1 part of SREBP/ADD1-binding sites (Delta SRE1/E box; M8, Delta SRE; M13, M14) caused moderate change in sterol regulatory response. Taken together, these results suggest that GC3 and CCAAT1 are essential to the sterol-mediated regulation of the Dhcr7 promoter. The data shown in Fig. 8 confirmed that the sequences located between nucleotides -33 and -25 are functional SRE-1 of the rat Dhcr7 promoter and behave as the direct repeat element 5'-PyCAPy-3', like other sterol-response genes (35, 36).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 8.   Mutational analysis of Dhcr7 promoter region. Transversal replacement mutations were introduced into the Dhcr7-luciferase chimeric construct, p7R318 (-287/+31). The Dhcr7 gene promoter-luciferase constructs are shown together with potential regulatory elements marked as boxes. HepG2 cells were transfected with one of the mutant reporter constructs and incubated in 5% LPDS in the presence of 10 µM Lovastatin (an induced condition) or 1.5 µg/ml 25-hydroxycholesterol (a suppressed condition) for 48 h. The data are expressed as "fold" activation by dividing the activity under sterol starvation (-sterol) by the activity under sterol supplement (+sterol).

Activation of Dhcr7 Promoter by SREBP-1-- Activation of Dhcr7 gene transcription by sterol starvation required GC3 and CCAAT1, in addition to the SRE1/E box (Fig. 8). Thus, co-regulatory transcription factors, such as Sp1 and NF-Y, may function in concert with SREBP-1 (ADD1) to mediate the sterol-regulatory response of the Dhcr7 gene (32, 37, 38). To test this, Dhcr7 transcription was measured by SREBP-1 co-transfection (24). As shown in Fig. 9A, the activity of Dhcr7-directed luciferase activity increased in a dose-dependent manner up to 50 ng when cells were co-transfected with pSREBP1. The activity of the Dhcr7 promoter by pSREBP1 was abolished when the sequence containing GC3 and CCAAT1 was deleted (Fig. 9B), suggesting that either Sp1 binding to GC3 or NF-Y binding to CCAAT1 is necessary for SREBP-1-mediated activation of the promoter. To further analyze the specificity and potential mechanism for this activation, we employed mutational analysis to find which regulatory element (i.e. GC3 or CCAAT1) is more critical for activation by SREBP-1 overexpression. These various point mutants in cis-acting elements of the Dhcr7 promoter were compared with wild type promoter for activation where the SREBP-1 was supplied exogenously from an expression plasmid. Interestingly, the mutation of CCAAT1 (M5, 6) and SRE1/E box (M8; Refs. 13 and 14) resulted in significant reduction (i.e. 35 and 58%) of SREBP activated Dhcr7 promoter activity as compared with the wild type (Fig. 10). However, mutation of GC3 (M2, 3) resulted in a less significant reduction of the activation rate when pSREBP1 plasmid was added. This result is also consistent with the data shown in Fig. 9B. A mutant construct of p7R148, in which GC3 was deleted, sustained 5.7-fold activation by co-transfection with pSREBP1. These results clearly demonstrate that SREBP-activated Dhcr7 promoter preferentially required the CCAAT1 element in HepG2 cells. However, GC3 site for Sp1 may contribute to the basal Dhcr7 promoter activity in response to sterol.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 9.   Differential SREBP-activated expression of rat Dhcr7 promoter. A, the p7R318 transfected HepG2 cells (50-70% confluence) were co-transfected with different amounts of pSREBP1 plasmid for 24 h and incubated in RPMI 1640 and 5% LPDS in the presence of 1.5 µg/ml 25-hydroxycholesterol to suppress endogenous SREBPs, and analyzed by a standard transient transfection assay for luciferase expression from a Dhcr7 promoter construct, p7R318. B, HepG2 cells were co-transfected with 50 ng of pSREBP1 and the indicated Dhcr7 promoter deletion constructs along with the reference plasmid pRL-SV40. After transfection, the cells were incubated in RPMI 1640 with 5% LPDS supplemented with 1.5 µg/ml 25-hydroxycholesterol. Values are means of three independent experiments.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 10.   Role of multiple regulatory elements of Dhcr7 promoter in SREBP-activated expression. Each reporter construct was co-transfected with pSREBP1 into HepG2 cell. After transfection, the cells were incubated in RPMI 1640 with 5% LPDS supplemented with 1.5 µg/ml 25-hydroxycholesterol. Indicated values are fold changes of the values from SREBP-1 expression experiment relative to control values. Data shown are mean ± S.D. (n = 4).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The purpose of this study was to determine how multiple motifs in the proximal promoter region are involved in sterol-mediated regulation of the Dhcr7 gene. Using combinations of deletion and site-specific mutations in the Dhcr7 promoter, we have identified and characterized cis-acting elements involved in the sterol-mediated regulation, which requires differential interaction of Sp1 (to GC3), NF-Y (to CCAAT1), and SREBP-1 (to SRE1/E box). (Fig. 3, Fig. 8 and Fig. 10). Mapping of the Dhcr7 promoter with respect to sterol-mediated gene expression was important for two reasons. First, Dhcr7 is involved in the final reaction of cholesterol biosynthesis, so control of gene expression by the end product (cholesterol) was intriguing. Second, since mutations of Dhcr7 genes already were found to be associated with SLOS, regulation of its gene expression should be critical for normal development. The results presented in this paper provided at least three interesting points with regard to Dhcr7 gene expression. First, rat Dhcr7 gene expression can be regulated by exogenous sterols including the end product, cholesterol (Fig. 1). In particular, 25-hydroxycholesterol effects seem dominant since induction of Dhcr7 promoter activity, mediated by sterol starvation condition, was abolished by this sterol regardless of the presence of cholesterol biosynthesis inhibitors (Fig. 5). Second, sterol-mediated Dhcr7 gene regulation appears to require participation of specific GC boxes (i.e. GC3 at -125/-120) and a CCAAT box (CCAAT1 at -88/-81) in addition to the SRE1/E box sequence (-33/-22). In addition, the most critical nucleotide sequence(s) in the SRE/E box was found to be Segment II of the SRE/E box ("5'-TCAC"-3', Table I) because mutation of this portion (i.e. M13 in Fig. 8) caused more change in sterol responsiveness of SRE/E box as compared with those in other segments (Segments I or III) of SRE/E box sequences, for example, M9, M10, and M11.

                              
View this table:
[in this window]
[in a new window]
 
Table I
SRE1/E box sequences of Dhcr7 promoter
Mutated bases are lower case.

Sequence analysis also revealed that the rat Dhcr7 promoter region contains high GC content and lacks a canonical TATA box, suggesting that it has overall similarity to promoters of HMG-CoA reductase and human squalene synthase in the cholesterol biosynthesis pathway and a number of housekeeping genes (29, 33, 39). Third, the fact that activation of Dhcr7 by addition of AY-9944 or Lovastatin led to a notion that the endogenous sterol can down-regulate the sterol-sensitive Dhcr7 gene, as evidenced by data in Fig. 1. Taken together, the maximal activation of Dhcr7 promoter by sterol starvation requires multiple cis-acting elements that are known to utilize the general transcription factors, NF-Y, Sp1, and ADD1, the rat homolog of SREBP-1, which may have some roles in recruiting SREBP-1, as well as activating it in these promoters. Although both NF-Y and Sp1 appear to work in a concerted manner in sterol-mediated regulation, the former participates in SREBP-1-mediated activation, while the latter acts in general transcription activation. A similar case may be the promoters of fatty acid synthase and the LDL receptor gene which require the SREBP-1 and generic co-regulator Sp1 for synergistic activation (34, 40). Recently, the synergistic activation by SREBP-1 and Sp1 has also been reviewed on an artificially assembled chromatin template in vitro and Sp1 has been shown to interact with NF-Ya in vitro in the absence of DNA (41, 42). Hence, it is believed that an interaction between NF-Y and Sp1 plays a crucial role in the sterol regulation of rat Dhcr7 promoter. Direct evidence should come from studies of promoter-factor interaction.

In conclusion, SLOS-related Dhcr7 is the first enzyme in the post-lanosterol pathway displaying a typical sterol-mediated gene regulation, thereby providing concerted, coordinated control of cholesterol biosynthesis between enzymes in the earlier pathway (HMG-CoA reductase and squalene synthase) and those in the distal pathway.

    ACKNOWLEDGEMENTS

We thank Drs. Bruce M. Spiegelman, Jae B. Kim, and Timothy F. Osborne for their kind provision of the expression plasmids.

    FOOTNOTES

* This work was supported in part by KOSEF, KDR Co. and Molecular Medicine project Grant 98-J03-02-04-A-03 (to Y. K. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Yonsei University, Dept. of Biochemistry, 134 Shinchon-dong, Sudaemoon-ku, Seoul, 120-749, Korea. Tel.: 82-2-2123-4242; Fax: 82-2-393-6589 or 362-9897; E-mail: paikyk@yonsei.ac.kr.

Published, JBC Papers in Press, March 13, 2001, DOI 10.1074/jbc.M101661200

2 J. N. Lee, S.-H. Bae, and Y.-K. Paik, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: Dhcr7, 7-dehydrocholesterol reductase; ADD1, adipocyte determination and differentiation-dependent factor 1; LPDS, lipoprotein-deficient serum; FBS, fetal bovine serum; SRE, sterol regulatory element; SREBP, SRE-binding protein; NF-Y, nuclear factor Y; EMSA, electrophoretic mobility shift assay; shh, sonic hedgehog; SLOS, Smith-Lemi-Opitz syndrome; PCR, polymerase chain reaction; bp, base pair(s); HMG, hydroxymethyl glutaryl.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Gibbon, G. F., Goad, L. J., Goodwin, T. W., and Nes, W. R. (1971) J. Biol. Chem. 246, 3967-3976[Abstract/Free Full Text]
2. Lee, J. N., and Paik, Y.-K. (1997) J. Biochem. Mol. Biol. 30, 370-377
3. Bae, S.-H., and Paik, Y.-K. (1997) Biochem. J. 326, 609-616[Medline] [Order article via Infotrieve]
4. Bae, S.-H., Lee, J. N., Fitzky, B. U., Seong, J., and Paik, Y.-K. (1999) J. Biol. Chem. 274, 14624-14631[Abstract/Free Full Text]
5. Porter, J. A., Young, K. E., and Beachy, P. A. (1996) Science 11, 255-259[CrossRef]
6. Cooper, M. K., Porter, J. A., Young, K. E., and Beachy, P. A. (1998) Science 5, 1603-1607[CrossRef]
7. Fitzky, B. U., Witsch-Baumgartner, M., Erdel, M., Lee, J. N., Paik, Y.-K., Glossmann, H., Utermann, G., and Moebius, F. F. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8181-8186[Abstract/Free Full Text]
8. Waterham, H. R., Wijburg, F. A., Hennekam, R. C., Vreken, P., Poll-The, B. T., Dorland, L., Duran, M., Jira, P. E., Smeitink, J. A., Wevers, R. A., and Wanders, R. J. (1998) Am. J. Hum. Genet. 63, 329-338[CrossRef][Medline] [Order article via Infotrieve]
9. Wassif, C. A., Maslen, C., Kachilele-Linjewile, S., Lin, D., Linck, L. M., Conner, W. E., Steiner, R. D., and Porter, F. D. (1998) Am. J. Hum. Genet. 63, 55-62[CrossRef][Medline] [Order article via Infotrieve]
10. Smith, D. W., Lemli, L., and Opitz, J. M. (1964) J. Pediatr. 64, 210-217[Medline] [Order article via Infotrieve]
11. Tint, G. S., Irons, M., Elias, E. R., Batta, A. K., Frieden, R., Chen, T. S., and Salen, G. (1994) N. Engl. J. Med. 13, 107-113
12. Irons, M., Elias, E. R., Tint, G. S., Salen, G., Frieden, R., Buie, T. M., and Ampola, M. (1994) Am. J. Med. Genet. 1, 347-352
13. Tint, G. S., Seller, M., Hughes-Benzie, R., Batta, A. K., Shefer, S., Genest, D., Irons, M., Elias, E., and Salen, G. (1995) J. Lipid Res. 36, 89-95[Abstract]
14. Alley, T. L., Gray, B. A., Lee, S. H., Scherer, S. W., Tsui, L. C., Tint, G. S., Williams, C. A., Zori, R., and Wallace, M. R. (1995) Am. J. Hum. Genet. 56, 1411-1416[Medline] [Order article via Infotrieve]
15. Honda, A., Batta, A. K., Salen, G., Tint, G. S., Chen, T. S., and Shefer, S. (1997) Am. J. Med. Genet. 31, 288-293[CrossRef]
16. Kelley, R. L., Roessler, E., Hennekam, R. C., Feldman, G. L., Kosaki, K., Jones, M. C., Palumbos, J. C., and Muenke, M. (1996) Am. J. Med. Genet 66, 478-484[CrossRef][Medline] [Order article via Infotrieve]
17. Shefer, S., Salen, G., Honda, A., Batta, A., Hauser, S., Tint, G. S., Honda, M., Chen, T., Holick, M. F., and Nguyen, L. B. (1997) Metabolism 46, 844-850[CrossRef][Medline] [Order article via Infotrieve]
18. Anderson, A. J., Stephan, M. J., Walker, W. O., and Kelley, R. I. (1998) Am. J. Med. Genet. 6, 413-418[CrossRef]
19. Porter, J. A., Ekker, S. C., Park, W. J., von Kessler, D. P., Young, K. E., Chen, C. H., Ma, Y., Woods, A. S., Cotter, R. J., Koonin, E. V., and Beachy, P. A. (1996) Cell 12, 21-34
20. Chiang, C., Litingtung, Y., Lee, E., Young, K. E., Corden, J. L., Westphal, H., and Beachy, P. A. (1996) Nature 383, 407-413[CrossRef][Medline] [Order article via Infotrieve]
21. Lanoue, L., Dehart, D. B., Hinsdal, M. E., Maeda, N., Tint, G. S., and Sulik, K. K. (1997) Am. J. Med. Genet. 73, 24-31[CrossRef][Medline] [Order article via Infotrieve]
22. Moebius, F. F., Fitzky, B. U., Lee, J. N., Paik, Y.-K., and Glossmann, H. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1899-1902[Abstract/Free Full Text]
23. Lecain, E., Chenivesse, X., Spagnoli, R., and Pompon, D. (1996) J. Biol. Chem. 271, 10866-10873[Abstract/Free Full Text]
24. Kim, J. B., Spotts, G. D., Halvorsen, Y. D., Shih, H. M., Ellenberger, T., Towle, H. C., and Spiegelman, B. M. (1995) Mol. Cell. Biol. 15, 2582-2588[Abstract]
25. Dignam, J. D., Levovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract]
26. Bennett, M. K., Ngo, T. T., Athanikar, J. N., Rosenfeld, J. M., and Osborne, T. F. (1999) J. Biol. Chem. 274, 13025-13032[Abstract/Free Full Text]
27. Dooley, K. A., Millinder, S., and Osborne, T. F. (1998) J. Biol. Chem. 273, 1349-1356[Abstract/Free Full Text]
28. Ericsson, J., Jackson, S. M., and Edwards, P. A. (1996) J. Biol. Chem. 271, 24359-24364[Abstract/Free Full Text]
29. Guan, G., Jiang, G., Koch, R. L., and Shechter, I. (1995) J. Biol. Chem. 270, 21958-21965[Abstract/Free Full Text]
30. Jackson, S. M., Ericsson, J., Mantovani, R., and Edwards, P. A. (1998) J. Lipid Res. 39, 767-776[Abstract/Free Full Text]
31. Natarajan, R., Ghosh, S., and Grogan, W. M. (1998) Biochem. Biophys. Res. Commun. 243, 349-355[CrossRef][Medline] [Order article via Infotrieve]
32. Sanchez, H. B., Yieh, L., and Osborne, T. F. (1995) J. Biol. Chem. 270, 1161-1169[Abstract/Free Full Text]
33. Spear, D. H., Kutsunai, S. Y., Correll, C. C., and Edwards, P. A. (1992) J. Biol. Chem. 267, 14462-14469[Abstract/Free Full Text]
34. Xiong, S., Chirala, S. S., and Wakil, S. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 3948-3953[Abstract/Free Full Text]
35. Magana, M. M., and Osborne, T. F. (1996) J. Biol. Chem. 271, 32689-32694[Abstract/Free Full Text]
36. Athanikar, J. N., and Osborne, T. F. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4935-4940[Abstract/Free Full Text]
37. Wang, X., Briggs, M. R., Hua, X., Yokoyama, C., Goldstein, J. L., and Brown, M. S. (1993) J. Biol. Chem. 268, 14497-14504[Abstract/Free Full Text]
38. Yieh, L., Sanchez, H. B., and Osborne, T. F. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6102-6106[Abstract/Free Full Text]
39. Dynan, W. S. (1986) Trends Genet. 8, 196-197
40. Bennett, M. K., and Osborne, T. F. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6340-6344[Abstract/Free Full Text]
41. Naar, A. M., Beaurang, P. A., Robinson, K. M., Oliner, J. D., Avizonis, D., Scheek, S., Zwicker, J., Kadonaga, J. T., and Tjian, R. (1998) Genes Dev. 12, 3020-3031[Abstract/Free Full Text]
42. Roder, K., Wolf, S. S., Larkin, K. J., and Schweizer, M. (1999) Gene (Amst.) 234, 61-69[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.